Back From The Dead Biodexa Makes Bid For VarianBio
Months After Bioasis Merger Collapsed
Having just avoided going into administration, the firm formerly known as Midatech has pivoted its business model from a drug delivery company to a therapeutics player and has hit the acquisition trail.
You may also be interested in...
Public Company Edition: Private Galderma raised $1bn but said its next likely financing will be an IPO. Also, Azitra went public while Turnstone, Apogee and Sagimet initiated the process; Sutro signed a royalty deal for up to $390m; and despite a follow-on offering mini-surge, cost cuts continue.
AvroBio retains rights to its other HSC gene therapy candidates. Alimera Acquires Further Commercial Rights To Eyepoint’s Uveitis Drug.
With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.